Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Matthias Klinger | Researchclopedia

Back to researchers

Matthias Klinger

Amgen (Germany)ORCID

49

Works

4,494

Citations

18

h-index

21

i10-index

Research Topics

Acute Lymphoblastic Leukemia research CAR-T cell therapy research Chronic Myeloid Leukemia Treatments

Affiliations

Goethe University Frankfurt2011–2011

Universität Ulm2008–2011

University of Würzburg2008–2008

Klinik und Poliklinik für Urologie2008–2008

Augenklinik Universitätsklinikum Würzburg2008–2008

Top Works

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf C. Bargou,Eugen Leo,et al.

20081,067 citations

Monoclonal and Polyclonal Antibodies Research

Lymphoma Diagnosis and Treatment

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp,Peter Kufer,et al.

2011905 citations

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp,Nicola Gökbuget,et al.

2012466 citations

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger,Christian Brandl,et al.

2012459 citations

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler,Stefan Knop,et al.

2016416 citations

Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class

Klaus Brischwein,Larissa Parr,et al.

2007188 citations

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier,Nicola Gökbuget,et al.

2015160 citations

Harnessing T cells to fight cancer with BiTE<sup>®</sup> antibody constructs – past developments and future directions

Matthias Klinger,Jonathan Benjamin,et al.

2016155 citations

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

Gerhard Zugmaier,Max S. Topp,et al.

201490 citations